Drug intelligence / Profile preview

porphysome

Development stage
Phase 1
Lead developer
University Health Network
Modality
Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Porphysomes are a class of self-assembled nanostructures composed of porphyrin-lipid subunits that form a bilayer vesicle similar to a liposome. Developed primarily at the University Health Network (Toronto) by Dr. Gang Zheng's lab, these nanoparticles are inherently theranostic, integrating multimodal imaging capabilities (fluorescence, photoacoustic, and PET when radiolabeled with isotopes like Copper-64) with therapeutic functions such as photodynamic therapy (PDT). In the context of cardiovascular disease, porphysomes can be functionalized with peptides like R4F to target scavenger receptor class B member 1 (SR-B1) on macrophages within atherosclerotic plaques. This targeting facilitates the identification of plaques via imaging and exerts athero-protective effects by promoting cholesterol efflux and reducing inflammatory responses. Clinical development is also exploring their utility in fluorescence-guided surgery and PDT for head and neck and lung cancers.

Other names
Porphyrin-lipid nanoparticles
02

Targets

SCARB1 (Scavenger receptor class B member 1)

Beyond the preview

Go deeper on porphysome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on porphysome.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call